Medivation
Adquirido por Pfizer
Essa empresa é sua?
Visão geral da empresa Medivation
Biotecnologia e farmacêuticaIndústria
Medivation Inc. (Nasdaq: MDVN) is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation’s goal is to transform the treatment of these diseases and offer hope to critically ill patients and their families. With the approval of Xtandi (enzalutamide) capsules in late August 2012 and the product launch immediately following, Medivation is continuing to build and develop a world-class workforce to take the company to the next strategic level.
Medivation was founded in 2004 by a group of experienced professionals with a long track record of working together successfully as a team. They founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch.
Medivation is a rapidly growing company with 650+ employees located in beautiful downtown San Francisco, CA. For additional information, please visit www.medivation.com.
Medivation was founded in 2004 by a group of experienced professionals with a long track record of working together successfully as a team. They founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch.
Medivation is a rapidly growing company with 650+ employees located in beautiful downtown San Francisco, CA. For additional information, please visit www.medivation.com.
